Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 30

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 30
---
purativa and Psoriatic Arthritis |

| • | Announced the screening of the first patients in the Phase 3 VELA program in Hidradenitis Suppurativa and in the Phase 3 IZAR program in Psoriatic Arthritis |

| • | Initiated clinical studies of SLK in additional indications, including a Phase 3 trial in adolescent patients with Hidradenitis Suppurativa (the VELA-TEEN trial), a Phase 2 trial in patients with Palmoplantar Pustulosis (the LEDA trial) and a Phase 2 trial in patients with Axial Spondyloarthritis (the S-OLARIS trial) |

| • | Signed a three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions utilizing Komodo’s technology and real-world data |

| • | Raised $52.5 million in additional capital to support the continued development of SLK and securing a projected cash runway to at least the end of 2026 |

| • | Grew company from approximately 50 to approximately 100 employees |

Shareholder Advisory Vote on Executive Compensation Each year, our shareholders are provided the opportunity to cast an advisory vote on the compensation of our named executive officers, or the “say-on-pay” vote, and the Compensation Committee considers the outcome of the prior year’s say-on-pay vote when making decisions relating to the compensation of our named executive officers and our executive compensation programs. We received 99% support for our say-on-pay proposal at our 2024 Annual Meeting, representing overall support of our executive compensation programs. We did not make any changes to our executive compensation programs as a result of the say-on-pay vote. Compensation Highlights Our Compensation Committee believes that executive compensation should be directly linked to short-term and long-term performance. A few of the key decisions made by the Compensation Committee aligned with such philosophy are as follows: Modest base salary adjustments : Base salaries for our named executive officers increased in July 2024 by 5.0% in local currency. Salary increases were generally based on competitive market positioning and take into account individual responsibilities, performance and experiences.

19

TABLE OF CONTENTS

Discretionary annual bonuses . Annual bonuses for our named executive officers paid out at 150% of target, based on a review of each named executive officer’s achievement of annual goals and objectives during the year. No annual equity awards : In 2024, none of our named executive officers received any equity awards. Compensation